TIXAGEVIMAB AND CILGAVIMAB

BRAND NAME	EVUSHELD
DRUG CLASS	Immunoglobulin (IgG1) monoclonal antibody (human), antiviral (SARS-CoV-2)
AVAILABILITY	There are **two vials** - use both vials to prepare the dose. one vial contains 150 mg/1.5 mL of tixagevimab (100 mg/mL) one vial contains 150 mg/1.5 mL of cilgavimab (100 mg/mL).[1] Also contain histidine, histidine hydrochloride monohydrate, sucrose and polysorbate-80.[1] The solutions are clear to opalescent and colourless to slightly yellow.[1]
WARNING	The occupational hazard of intermittent low dose exposure to tixagevimab and cilgavimab and is not known. Wear a mask and gloves when preparing the dose to minimise exposure. Hypersensitivity reactions including anaphylaxis may occur. Resuscitation facilities must be readily available.[1]
pH	6[1]
PREPARATION	To prepare a 300 mg dose (150 mg of tixagevimab and 150 mg of cilgavimab) for pre-exposure prophylaxis: draw up 150 mg/1.5 mL of tixagevimab and 150 mg/1.5 mL of cilgavimab into separate syringes suitable for IM use.[1,2]
STABILITY	Vials: store at 2 to 8 °C. Do not freeze. Protect from light. **Do not shake**.[1] The solutions are stable in a syringe for 4 hours at 25 °C or at 2 to 8 °C.[1]
ADMINISTRATION	
IM injection	Inject the tixagevimab dose into the gluteal muscle, then inject the cilgavimab dose into the opposite gluteal muscle.[1] The ventrogluteal site is preferred.
SUBCUT injection	Not recommended
IV injection	Not recommended
IV infusion	Not recommended
COMPATIBILITY	Do not mix with other medicines
INCOMPATIBILITY	No information
SPECIAL NOTES	Hypersensitivity reactions including rash and urticaria may occur.[1] Check your local guidelines for monitoring requirements. Clinical trial participants were monitored for adverse effects for at least 1 hour after the injections.[3] Anaphylactic reactions are rare but are a medical emergency. Commence treatment immediately.[1] Pain, redness and itching at the injection sites are common.[1]

REFERENCES

1. Product information. Available from www.tga.gov.au. Accessed 07/04/2022.
2. National COVID-19 Clinical Evidence Taskforce. Australian guidelines for the clinical care of people with COVID-19: 6.1.9.1 Tixagevimab plus cilgavimab (Evusheld). Available from www.covid19evidence.net.au. Accessed 08/04/2022.
3. Levin MJ, Ustianowksi A, De Wit S, Launay O, Avila A, Templeton A, et al. Intramuscular AZD7442 (Tixagevimab- Cilgavimab) for prevention of COVID-19. N Engl J Med 2022; Apr 20. DOI: 10.1056/NEJMoa2116620.